Kelly Heilman, APRN
Adult Health · Glastonbury, CTNPI 1316497662
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 368 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by GSK at 27.0% of the total. Reporting peaked in 2022 at $2,352 and has fallen 60.5% since, to $930 in 2025. Among adult health clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 368 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$585
- Amgen$370
- AbbVie$351
- plus $2K from 19 others
What the payments were for
- Food & beverage$7,08099%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 128 | $1,929 |
| AstraZeneca | 43 | $1,151 |
| Regeneron Healthcare Solutions, Inc. | 46 | $1,140 |
| Sanofi | 26 | $585 |
| Amgen | 18 | $370 |
| AbbVie | 21 | $351 |
| Optinose US, Inc. | 14 | $311 |
| Boehringer Ingelheim | 14 | $260 |
| CSL Behring | 6 | $170 |
| Novartis | 19 | $157 |
| Blueprint Medicines Corporation | 2 | $140 |
| Biocryst US Sales Co., LLC | 7 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $107 |
| LEO Pharma Inc. | 3 | $50 |
| Genentech USA, Inc. | 3 | $44 |
| Pfizer | 2 | $39 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| Pharming Healthcare, Inc. | 2 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $25 |
| Ionis Pharmaceuticals, Inc. | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| USWM, LLC | 1 | $19 |
| Alk-abello, Inc | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$504
- TEZSPIRE$250
- TRELEGY ELLIPTA$241
- NUCALA$125
- AYVAKIT$122
How this compares
$7,145 in reported general payments places this provider in the 90th percentile of 418 adult health providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 23 | $66,041 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $63,960 |
| TezspireTezepelumab-Ekko | 11 | $47,048 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $25,399 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $17,252 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $4,727 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $4,350 |
| Fluticasone Propionate HfaFluticasone Propionate | 18 | $3,854 |
| Azelastine Hcl | 120 | $3,727 |
| Epinephrine | 16 | $2,925 |
| Mometasone Furoate | 22 | $2,498 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 82 | $2,098 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $1,955 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,456 |
| Montelukast Sodium | 122 | $1,301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,929 | $89,359113 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,151 | $69,02749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 418 adult health providers in Connecticut.
Other adult health in Glastonbury
- Nanette AlexanderGlastonbury$14K
- Jennifer KaranianGlastonbury$9K
- Leah EhleManchester$418K
- Laura MulkaWethersfield$306K
- Gretchen MichaelsonSouth Windsor$169K
- Kimberly RyanWethersfield$74K
- Kathryn JackMeriden$67K
- Lynn RapsilberTorrington$52K
- Genice NelsonFarmington$36K
- Andrea LauterNew London$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.